Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).
Novartis has launched two trials pitching Cosentyx head-to-head with AbbVie’s Humira and one of its own biosimilars in a bid to increase its presence in a highly competitive market. Cosentyx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback